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ABSTRACT
The 3-year FREEDOM trial assessed the efficacy and safety of 60mg denosumab every 6 months for the treatment of postmenopausal
women with osteoporosis. Participants who completed the FREEDOM trial were eligible to enter an extension to continue the evaluation
of denosumab efficacy and safety for up to 10 years. For the extension results presented here, women from the FREEDOM denosumab
group had 2 more years of denosumab treatment (long-term group) and those from the FREEDOM placebo group had 2 years of
denosumab exposure (cross-over group). We report results for bone turnover markers (BTMs), bonemineral density (BMD), fracture rates,
and safety. A total of 4550 women enrolled in the extension (2343 long-term; 2207 cross-over). Reductions in BTMs were maintained
(long-term group) or occurred rapidly (cross-over group) following denosumab administration. In the long-term group, lumbar spine and
total hip BMD increased further, resulting in 5-year gains of 13.7% and 7.0%, respectively. In the cross-over group, BMD increased at the
lumbar spine (7.7%) and total hip (4.0%) during the 2-year denosumab treatment. Yearly fracture incidences for both groups were below
rates observed in the FREEDOM placebo group and below rates projected for a ‘‘virtual untreated twin’’ cohort. Adverse events did not
increase with long-term denosumab administration. Two adverse events in the cross-over group were adjudicated as consistent with
osteonecrosis of the jaw. Five-year denosumab treatment of women with postmenopausal osteoporosis maintained BTM reduction and
increased BMD, and was associated with low fracture rates and a favorable risk/benefit profile.  2012 American Society for Bone and
Mineral Research.
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Introduction
Increased bone resorption after menopause leads to loss ofbone mass and microstructural deterioration which signifi-
cantly increase fracture risk. Receptor activator of NF-kB (RANK)
ligand plays an essential role in mediating resorption through
osteoclast formation, function, and survival.(1,2) Denosumab is a
fully human monoclonal antibody that inhibits RANK ligand.
In the pivotal, 3-year, placebo-controlled FREEDOM trial,(3)
administration of 60mg denosumab subcutaneously every
6 months to postmenopausal women with osteoporosis signifi-
cantly reduced bone turnover markers (BTMs), increased bone
mineral density (BMD), and reduced new vertebral, hip, and
nonvertebral fractures by 68%, 40%, and 20%, respectively.
Osteoporosis is a chronic disease requiring long-term
treatment. Therefore, characterization of the long-term efficacy
and safety of denosumab is essential for clinical practice.
Accordingly, FREEDOM has been extended, in an open-label
design, for an additional 7 years, during which all participants
receive denosumab. The extension includes two populations:
those who had received denosumab for 3 years during the core
trial (long-term group) and those who had received placebo for
3 years during the core trial (cross-over group). We report the
effects of denosumab on BTMs, BMD, fracture rates, and safety
for the first 2 years of the extension.
Patients and Methods
Study design
The FREEDOM core trial design and results have been
published.(3) In short, FREEDOM was a phase 3, randomized,
double-blind, placebo-controlled, 3-year, global study. Enrolled
women were aged 60 to 90 years with a lumbar spine or total hip
BMD T-score between 2.5 and 4.0 at either site. Participants
were randomized to receive 60mg denosumab (Prolia1; Amgen
Inc., Thousand Oaks, CA) or placebo subcutaneously every
6 months for 3 years, in addition to daily calcium (1 g) and
vitamin D (400 IU). All women who completed the core trial (ie,
completed their 3-year visit, did not discontinue investigational
product, and did not miss >1 dose) were eligible to enter the
extension. During the extension, all participants are scheduled
to receive 60mg denosumab subcutaneously every 6 months
for 7 years with daily calcium and vitamin D (Fig. 1). The study is
ongoing and the preplanned data analyses reported here
include the first 2 years of the extension, representing up to 5
years of continued denosumab exposure.
The study protocol was approved by an ethics committee or
institutional review board for each site. Participants provided
written informed consent. Representatives of the sponsor,
Amgen Inc., designed the study in collaboration with investi-
gators, and conducted the statistical analysis according to a
prespecified plan.
Study procedures
In the 7-year extension trial, main study visits are scheduled to
occur at baseline (corresponding to the end of the core trial) and
every 6 months for 7 years. Participants are scheduled to receive
60mg denosumab subcutaneously every 6 months (1 month)
for 7 years beginning on day 1. For this report, all efficacy and
safety assessments continued with the same methodology used
during FREEDOM.(3) Measurements of serum C-terminal telopep-
tide of type 1 collagen (CTX) and procollagen type I N-terminal
propeptide (P1NP) were obtained from a subset of women who
participated in the FREEDOM BTM substudy and continued in the
extension (CTX: baseline, day 10, and months 3, 4, 6, 12, and 24;
P1NP: baseline, day 10, and months 6, 12, and 24). Undetectable
values were imputed using the corresponding assay’s estab-
lished lower limit of detection value (CTX, 0.049 ng/mL; P1NP,
10mg/L) as previously reported.(4) BMD measurements were
performed by dual-energy X-ray absorptiometry (DXA) at the
lumbar spine and proximal femur (all women) and at the 1/3
radius (subset of women). Vertebral fractures were identified by a
central facility (Synarc, Inc.) using the Genant semiquantitative
grading scale using thoracic and lumbar lateral radiographs
obtained at extension baseline and year 2.(5) A prevalent fracture
at baseline was defined as a vertebral body with a semiquanti-
tative grade of1. As was prespecified in the original protocol, a
new vertebral fracture was identified when there was 1 grade
increase from a previous grade of 0 in any vertebra between T4
and L4, excluding fractures associated with high trauma severity
or a pathologic fracture. Nonvertebral fractures included low-
trauma fragility fractures only, as defined previously.(3) Clinical
fractures required confirmation by diagnostic imaging or a
radiologist’s report. At all study visits, adverse events (AEs),
clinical fracture information, and concomitant medications were
recorded. Each potential case of osteonecrosis of the jaw (ONJ)
was reviewed by an independent, masked, external, expert
adjudication committee, as described previously.(6)
Statistical analyses
The primary objective of the extension is to describe the safety
and tolerability of denosumab. Secondary objectives include
evaluation of the changes in BTMs and BMD, and the incidence
of vertebral and nonvertebral fractures.
Safety analyses included participants who received 1 dose
of investigational product. New adverse events occurring during
the extension were coded using the Medical Dictionary for
Regulatory Authorities (MedDRA v13.0). For consistency,
MedDRA v13.0 will be used for coding and reporting adverse
events for the duration of the extension study. The analyses of
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Fig. 1. Study design showing the 3-year FREEDOM study and the 7-year
extension. The data reported here are for the first 2 years of the extension
study. SC¼ subcutaneous; Q6M¼ every 6 months.
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AEs were descriptive and included exposure-adjusted subject
incidence rates. Analyses of BTM percent change from baseline
required observed values at baseline and the time points of
interest. Results are presented as medians and interquartile
ranges. Analyses of BMD percent change from baseline required
observed values at baseline and the time points of interest.
Percent changes in BMD were analyzed using the likelihood-
based repeated measures model(7) including treatment, age
stratification variable, visit, baseline value, densitometer type,
treatment-by-visit interaction, and baseline value-by-densitom-
eter type interaction as fixed effects using an unstructured
variance-covariance structure. Visit was treated as a categorical
variable. Kenward and Roger’s approach(8) was followed for
estimating the denominator degrees of freedom for the
hypothesis test. Results are presented as least squares means
with 95% confidence intervals. Finally, we calculated crude
subject incidence rates for new vertebral fracture (multiple
fracture occurrences were counted once per subject) and
Kaplan-Meier estimates of the cumulative incidence of non-
vertebral fracture.
Because all subjects in the extension received denosumab, we
used a simulation method developed for such an extension
study design(9) to estimate expected fracture rates in a
hypothetical cohort of long-term placebo controls (so-called
‘‘virtual twins’’), with the baseline characteristics of the long-term
denosumab subjects. First, linear, Poisson, and logistic prediction
models were developed using actual FREEDOM data on BMD,
fracture history, body mass index, age, and smoking status for
subjects who received placebo during the 3 years of FREEDOM
and enrolled in the extension study. These models were then
used to predict fracture outcomes for the denosumab-treated
women who entered the extension had they received placebo
for 5 years (virtual twins).
Final FREEDOM data were reported previously,(3) and are
summarized in this manuscript to illustrate the extension
results. For BTMs and BMD, only data from women enrolled in
the extension are presented.
Results
Of the 7808 participants enrolled in the core trial, 5928 (76%)
were eligible for enrollment in the extension (ie, completed their
3-year visit, did not discontinue investigational product [IP], and
did not miss >1 dose) (Fig. 2). Of these, 4550 (2343 long-term,
2207 cross-over) enrolled in the extension, corresponding to 77%
of those eligible to enroll and 58% of those enrolled in the
original FREEDOM study. By year 2, 3782 (83% of those enrolled)
remained on study. The long-term and cross-over groups
address two distinct considerations: (1) the impact of continued
denosumab administration past 3 years, and (2) the reproduc-
ibility of the FREEDOM results. Each group is described separately
below.
Long-term denosumab group
Baseline characteristics
FREEDOM and extension baseline characteristics for the
participants in the long-term group are shown in Table 1. At
the start of the extension, 53.7% were 75 years old. The
proportion of patients with prevalent vertebral fractures was
similar (23.9% at FREEDOM baseline versus 24.5% at extension
baseline). At the extension baseline, the BMD T-scores were
improved and the BTM values remained low.
BTMs
Changes in serum CTX and P1NP are shown for 65 long-term
denosumab women who participated in the BTM substudy
(Fig. 3). After the seventh dose of denosumab (the first extension
dose), reductions in CTX during the first 4 months and P1NP at
6 months were consistent with those observed after the first
dose of denosumab during the core trial. The mean and median
BTM values remained below FREEDOM pretreatment values
throughout the 5 years of continued denosumab treatment.
The reduction of BTMs showed an attenuation at the end of
the dosing interval, as expected based on denosumab
pharmacokinetics.(4) Although the small number of subjects
with BTM values limits the robustness of the interpretation,
the increases in BTMs at the end of the dosing interval appeared
to increase with time in the study, an observation also reported
within FREEDOM.(4)
BMD
Despite the apparent increase over time in the release of BTMs,
there were further significant gains in BMD during the fourth and
fifth years of denosumab treatment at the lumbar spine (1.9%
and 1.6%, respectively), total hip (0.8% and 0.6%, respectively),
and femoral neck (0.9% and 0.4%, respectively) (Fig. 4). A
significant gain in BMD at the 1/3 radius was also observed
during the fourth year of treatment (0.6%) but not during the
fifth year (0.3%). Increases in BMD over 5 years of continued
denosumab treatment reached 13.7% (lumbar spine), 7.0% (total
hip), 6.1% (femoral neck), and 2.3% (1/3 radius) (all p< 0.0001).
Fractures
During FREEDOM, denosumab reduced the risk of new vertebral
and nonvertebral fractures during each year of the trial,
compared with placebo (Fig. 5A, B). In the extension, fracture
incidence rates remained low and below those observed in the
core trial placebo group. They also were below the estimated
fracture incidence rates expected had the denosumab subjects
who enrolled in the extension received placebo (twin-estimated
placebo). Specifically, 2.8% (n¼ 59) of the women in the
long-term denosumab group experienced 1 new vertebral
fracture through year 2 of the extension (annualized rate of 1.4%
for the fourth and fifth years of denosumab treatment). Fourteen
women had a clinical vertebral fracture. Additionally, 1.4% and
1.1% of women in the long-term denosumab group experienced
a nonvertebral fracture during the fourth and fifth years of
denosumab exposure. The most common nonvertebral fractures
in the long-term group during the first 2 years in the extension
were wrist (n¼ 21), rib (n¼ 9), hip (n¼ 7), and ankle (n¼ 7) (with
n¼ the number of affected women).
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Adverse events
In the long-term group, the subject incidence rates per 100
subject-years for all, serious, and fatal AEs during the extension
were similar to or lower than those in the placebo and
denosumab groups during the core trial (Table 2). For example,
the subject incidence rates of AEs reported by the placebo and
denosumab groups during the core trial were 156.1 and 154.3,
respectively, compared with 113.2 in the long-term denosumab
group during the extension. The subject incidence rates of
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Fig. 2. Disposition of all participants. All women who completed FREEDOM (ie, completed their 3-year visit, did not discontinue investigational product
[IP], and did not miss >1 dose) were eligible to participate in the FREEDOM extension. aTwo women who discontinued denosumab also entered the
extension in the long-term denosumab group.
Table 1. Baseline Characteristics
Long-term denosumab treatment,
Extension subjects (N¼ 2343)
Cross-over denosumab treatment,
Extension subjects (N¼ 2207)
FREEDOM baseline Extension baseline FREEDOM baseline Extension baseline
Age (years) 71.9 (5.0) 74.9 (5.0) 71.8 (5.1) 74.8 (5.1)
Age groups, n (%)
65 years 2209 (94.3) 2294 (97.9) 2067 (93.7) 2149 (97.4)
75 years 662 (28.3) 1258 (53.7) 624 (28.3) 1151 (52.2)
Years since menopause 23.7 (7.3) 26.7 (7.3) 23.7 (7.4) 26.7 (7.4)
Prevalent vertebral fractures, n (%) 559 (23.9) 573 (24.5) 485 (22.0) 551 (25.0)
Lumbar spine BMD T-score 2.83 (0.67) 2.14 (0.80) 2.84 (0.68) 2.81 (0.75)
Total hip BMD T-score 1.85 (0.79) 1.50 (0.79) 1.85 (0.79) 1.93 (0.80)
CTXa (ng/mL), median (IQR) 0.524 (0.363–0.710) 0.183 (0.081–0.556) 0.554 (0.420–0.657) 0.568 (0.413–0.718)
P1NPa (mg/L), median (IQR) 46.7 (34.0–58.2) 17.5 (11.0–26.0) 54.2 (40.0–65.7) 48.8 (35.0–65.8)
Data are mean with standard deviations (SD) unless otherwise noted.
BMD¼bone mineral density; CTX¼C-terminal telopeptide of type 1 collagen; IQR¼ interquartile range; N¼number of subjects enrolled in the
extension; P1NP¼procollagen type I N-terminal propeptide.
aBTM subsets include 65 subjects in the long-term group and 36 subjects in the cross-over group.
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serious AEs were 10.4, 10.6, and 10.8 in the FREEDOM placebo,
FREEDOM denosumab, and extension long-term denosumab
groups, respectively. Rates of skin infection were low. There were
no atypical femoral fractures or adjudicated ONJ events in the
long-term group during the first 2 years of the extension.1
Cross-over denosumab group
Baseline characteristics
Characteristics of the cross-over denosumab group at FREEDOM
and extension baseline are shown in Table 1. At the start of the
extension, 52.2%were75 years old. Prevalent vertebral fracture
rates in the placebo participants increased during the core trial as
reflected in the baseline characteristics for this group: 25.0% at
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Fig. 3. Percent change in bone turnover markers during FREEDOM and the extension. Changes in serum C-terminal telopeptide of type 1 collagen (CTX;
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in a substudy of bone turnover markers. Data are median (interquartile range).
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extension baseline versus 22.0% at FREEDOM baseline. The
cross-over baseline BTM values and BMD T-scores were similar
to core trial baseline values, consistent with the treatment
of these participants with calcium and vitamin D during the
core trial.
BTMs
Changes in serum CTX and P1NP are shown for 36 cross-over
women who participated in the BTM substudy (Fig. 3). Following
the initial administration of denosumab, a rapid and marked
Fig. 5. Yearly incidence of new vertebral fractures (A and C) and nonvertebral fractures (B and D) during FREEDOM and the extension. n¼ number of
subjects with1 fracture. N¼ number of subjects in the primary efficacy analysis set who were still on study at the beginning of each period. Annualized
rate: (2-year rate/2).
Table 2. Exposure-Adjusted Subject Incidence of Adverse Events
Placebo Denosumab
FREEDOM,
years 1–3
(N¼ 3883),
rate (n)
FREEDOM,
years 1–3
(N¼ 3879),
rate (n)
Extension, long-term,
years 4–5
(N¼ 2343),
rate (n)
Extension, cross-over,
years 1–2
(N¼ 2206),
rate (n)
Adverse events 156.1 (3614) 154.3 (3598) 113.2 (1955) 111.4 (1826)
Infection 30.7 (2113) 29.3 (2052) 25.1 (875) 27.4 (886)
Malignancy 1.6 (167) 1.8 (187) 2.0 (87) 1.6 (68)
Eczema 0.6 (67) 1.1 (119) 1.1 (47) 0.9 (39)
Hypocalcemia <0.1 (3) 0.0 (0) <0.1 (1) 0.1 (5)
Pancreatitis <0.1 (3) <0.1 (7) <0.1 (1) <0.1 (1)
Serious adverse events 10.4 (974) 10.6 (1002) 10.8 (442) 11.1 (428)
Infections 1.3 (134) 1.5 (160) 1.2 (55) 1.5 (63)
Cellulitis or erysipelas <0.1 (1) 0.1 (12) <0.1 (3) <0.1 (1)
Fatal adverse events 0.8 (90) 0.6 (70) 0.6 (26) 0.8 (32)
Treatment groups are based on the original randomized treatments received in FREEDOM. All subjects in the extension are receiving denosumab.
n¼ total number of subjects with an adverse event; N¼number of subjects who received1 dose of investigational product; rate¼ exposure-adjusted
subject incidence per 100 subject-years.
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reduction in serum CTX occurred, followed by a reduction in
serum P1NP. Both changes were nearly identical with those
observed in the denosumab group at the beginning of
the core trial. At the end of the dosing interval, attenuation
of bone turnover reduction was observed, as seen during
FREEDOM.(4) Throughout the first 2 years of denosumab
treatment, the BTMs remained below their pretreatment values.
BMD
BMD increased significantly following denosumab administra-
tion (Fig. 4). BMD gains from extension baseline were 7.7%
(lumbar spine), 4.0% (total hip), 3.3% (femoral neck), and 0.3%
(1/3 radius) after 2 years of denosumab administration. Similar
BMD gains were observed in the FREEDOM denosumab group
during the first 2 years: 7.8% (lumbar spine), 4.7% (total hip), 4.0%
(femoral neck), and 2.1% (1/3 radius).
Fractures
The yearly incidence (annualized rate) of new vertebral fractures
for the cross-over group was 0.9% (n¼ 34), similar to the 0.7%
observed in the core trial for the first 2 years for the group that
received denosumab (Fig. 5C). Three women had a clinical
vertebral fracture. For nonvertebral fractures, the yearly
incidence for the cross-over group was 2.4% and 1.7% during
years 1 and 2 of the extension, respectively. These rates also were
similar to the nonvertebral fracture incidences in the FREEDOM
denosumab group andwere below the year 1 and 2 nonvertebral
fracture rates observed in the FREEDOM placebo group (Fig. 5D).
Both the new vertebral and nonvertebral fracture rates for the
cross-over group were below the estimated fracture incidence
for the virtual twin-estimated placebo group. The most common
nonvertebral fractures in the cross-over group during the first 2
years in the extension were wrist (n¼ 30), hip (n¼ 14), ankle
(n¼ 13), and foot (n¼ 9).
Adverse events
The subject incidences of all, serious, and fatal AEs in the cross-
over group during the first 2 years of the extension were similar
to or lower than those reported by the FREEDOM placebo and
denosumab groups (Table 2). For example, the subject incidence
rates of AEs reported by the placebo and denosumab
groups during the core trial were 156.1 and 154.3, respectively,
compared with 111.4 for the cross-over denosumab group
during the extension. The subject incidence rates of serious AEs
were 10.4, 10.6, and 11.1 for the FREEDOM placebo, FREEDOM
denosumab, and extension cross-over denosumab groups,
respectively. There were no atypical femoral fractures. Two
oral AEs (bone necrosis and osteomyelitis) were adjudicated
as consistent with ONJ. Both lesions healed completely: one
within 137 days and the other within 227 days. In one woman,
healing occurred within the 6-month dosing interval and she
continued to receive denosumab (two further doses) without
further oral events. In the other woman, healing occurred
after the 6-month dosing interval and denosumab was
permanently discontinued. There was only one serious skin
infection (erysipelas) in the cross-over group.
Discussion
The extension trial enrolled women who had received
denosumab or placebo in the FREEDOM trial,(3) and therefore
provides an opportunity to evaluate the long-term efficacy and
safety of continued denosumab administration (long-term
group), and to reproduce the denosumab data observed in
FREEDOM during the first 2 years of therapy (cross-over
group).
BMD and BTMs are the main intermediate efficacy measures
that are associated with anti-fracture efficacy of antiresorptive
drugs for the treatment of osteoporosis.(10) The present study
demonstrates that in participants who continued denosumab
for a fourth and fifth year, the bone density measurements
continued to increase, and the turnover markers were main-
tained at substantially lower than pretreatment levels, but no
lower than those achieved early in the core trial. The data
from the cross-over group confirmed the findings from the
FREEDOM trial.
Phase three trials for anti-osteoporotic agents generally have
placebo control arms, but the placebo assignment cannot be
continued indefinitely in consideration of the well-being of those
participants.(11–13) However, long-term exposure is important for
assessment of both safety and efficacy of this chronic condition.
The efficacy assessments are limited by the lack of an ongoing
control group. Projections based on the fracture rate of the
placebo group, adjusted for age, have been used as a referent in
an effort to address this problem.(14) Subsequently, a more
sophisticated model has been developed and validated.(9) In the
FREEDOM study, the use of the placebo group to generate data
for such a model was planned, and for the present report, this
independently-validated model was used to project fracture
rates for a virtual group of placebo-treated ‘‘twins’’ of the
participants. This model takes into account several risk factors.
While this method provides a useful tool for assessing treatment
efficacy, it rests on the unverifiable assumption that outcomes
for the virtual twins can be predicted without bias from
the available data. Simulations suggest that the method is
reasonably robust against selection bias, but vulnerable to
secular trends in the underlying fracture risk.(9) Although there
are inherent limitations to the inferences drawn from such
models, fracture rates for the extension and cross-over groups
were consistently below these estimates.
A main objective of the extension is to describe the safety of
denosumab. The subject incidences of all, serious, and fatal AEs
during the first 2 years of the extension were similar to or lower
than those reported by the FREEDOM placebo and denosumab
groups. Incidences of malignancy and infection (such as
cellulitis or erysipelas) were low and showed no trend toward
increases over time, and there was only a single serious skin
infection in the cross-over group. There were no atypical femoral
fractures in either group. Although cases of ONJ have now been
observed in patients receiving denosumab, the incidence
remains low.
Thus, our findings demonstrate a progressive increase in bone
density and sustained but not progressive decrease in bone
turnover, and are consistent with maintenance of anti-fracture
efficacy. There was no apparent increase in the risk of AEs with
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extended exposure. The cross-over group sustained a single
serious skin infection and two events adjudicated as ONJ,
while confirming the previous efficacy observations. Denosumab
remained a useful medication for osteoporosis over 5 years of
exposure.
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